ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Galecto Inc

Galecto Inc (GLTO)

0.6211
-0.0089
(-1.41%)
Closed May 17 4:00PM
0.6211
0.00
(0.00%)
After Hours: 6:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.6211
Bid
0.622
Ask
0.645
Volume
44,149
0.6157 Day's Range 0.6388
0.50 52 Week Range 3.70
Market Cap
Previous Close
0.63
Open
0.63
Last Trade
10
@
0.6221
Last Trade Time
Financial Volume
$ 27,648
VWAP
0.626234
Average Volume (3m)
198,136
Shares Outstanding
27,112,697
Dividend Yield
-
PE Ratio
-0.45
Earnings Per Share (EPS)
-1.41
Revenue
-
Net Profit
-38.35M

About Galecto Inc

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Galecto Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GLTO. The last closing price for Galecto was $0.63. Over the last year, Galecto shares have traded in a share price range of $ 0.50 to $ 3.70.

Galecto currently has 27,112,697 shares outstanding. The market capitalization of Galecto is $17.08 million. Galecto has a price to earnings ratio (PE ratio) of -0.45.

GLTO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0727-10.47852407030.69380.7150.61151947020.65351597CS
4-0.0899-12.64416315050.7110.740.61151176520.68031931CS
12-0.0438-6.587456760420.66490.940.61981360.76316811CS
260.02173.620286953620.59940.940.55612745470.69209306CS
52-1.7589-73.90336134452.383.70.53662160.95535614CS
156-4.2389-87.22016460914.8616.410.52787843.07880735CS
260-15.1489-96.061509194715.7717.990.52416293.25886624CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 1.65
(313.74%)
104.67M
FLJFLJ Group Limited
$ 1.54
(220.90%)
57.28M
JFBRJeffs Brands Ltd
$ 0.6276
(102.45%)
37.97M
IPWiPower Inc
$ 2.89
(97.95%)
11.05M
CETXCemtrex Inc
$ 0.4851
(48.58%)
21.22M
BSFCBlue Star Foods Corporation
$ 0.0757
(-45.26%)
60.09M
SINTSiNtx Technologies Inc
$ 0.084602
(-39.57%)
156.33M
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
HSCSHeart Test Laboratories Inc
$ 7.00
(-38.11%)
348.9k
AMPGAmplitech Group Inc
$ 1.46
(-32.09%)
613.31k
CRKNCrown Electrokinetics Corporation
$ 0.171
(-28.75%)
1.73B
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
GWAVGreenwave Technology Solutions Inc
$ 0.1541
(4.05%)
1.16B
AKANAkanda Corporation
$ 0.1726
(30.26%)
566.3M
PEGYPineapple Energy Inc
$ 0.1053
(-28.85%)
219.2M

GLTO Discussion

View Posts
Retire43 Retire43 1 week ago
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

πŸ‘οΈ0
Retire43 Retire43 4 weeks ago
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
πŸ‘οΈ0
Retire43 Retire43 5 months ago
https://www.zerohedge.com/news/2023-12-12/disease-x-resistance-futile
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 8 months ago
glto on the move
πŸ‘οΈ0
subslover subslover 8 months ago
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction. There can be no assurance that its exploration will result in Galecto pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.

In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount.

Galecto has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its programs unless and until it is determined that further disclosure is appropriate or necessary.

As of June 30, 2023, Galecto’s cash, cash equivalents and investments balance was $52.1 million.
πŸ‘οΈ0
Retire43 Retire43 8 months ago
Please share this!

Science buff #Investor #vaccinated #unvaccinated #COVID19 #LongCovid #Covid #masks #masksdontwork we want all to hear about a new paradigm in #drug development. $BIXT @buffalofireside talk about #galectin #drugs & potent #antiviral https://t.co/vma2hIy6CY @EnemyInAState pic.twitter.com/ARIwmsS65t— Mike Sheikh (@MikeSheikh2) September 20, 2023
πŸ‘οΈ0
Retire43 Retire43 8 months ago
Look at this Reprint. Share this !

https://www.preprints.org/manuscript/202309.0077/v1
πŸ‘οΈ0
Retire43 Retire43 8 months ago
https://www.zerohedge.com/news/2023-09-12/mask-mandates-unpopular-due-existence-next-gen-antivirals-pipeline
πŸ‘οΈ0
Retire43 Retire43 8 months ago
Did anyone catch this today ?

H.C. Wainwright 25th Annual Global Investment Conference

Date: Monday, September 11, 2023
Time: 7:00 am ET
Location: New York City, NY
πŸ‘οΈ0
Butchmass Butchmass 9 months ago
When is this company going to start doing more to publicize itself. They could be more up front and active with the share holders.
πŸ‘οΈ0
Triple nickle Triple nickle 9 months ago
Added a few down here
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
Damn shame
Sold quite a while ago at a profit
πŸ‘οΈ0
TheFinalCD TheFinalCD 9 months ago
$GLTO (.80) -65% Galecto to discontinue development of lung disease treatment
Reuters
Tue, August 15, 2023 at 7:35 AM EDT

Aug 15 (Reuters) - Galecto Inc said on Tuesday it will dicontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)

https://finance.yahoo.com/news/galecto-discontinue-development-lung-disease-113556937.html
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
GLTO now ;No 11; on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
GLTO new 52/week high
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Butchmass Butchmass 10 months ago
Monksdream, I hope we see considerable more traffic on this board soon. Earnings coming out 7/28/2023.
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
GLTO No 3 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0